MA37291A3 - Macrocyclic derivatives for the treatment of proliferative diseases - Google Patents

Macrocyclic derivatives for the treatment of proliferative diseases

Info

Publication number
MA37291A3
MA37291A3 MA37291A MA37291A MA37291A3 MA 37291 A3 MA37291 A3 MA 37291A3 MA 37291 A MA37291 A MA 37291A MA 37291 A MA37291 A MA 37291A MA 37291 A3 MA37291 A3 MA 37291A3
Authority
MA
Morocco
Prior art keywords
treatment
compounds
proliferative diseases
salts
macrocyclic derivatives
Prior art date
Application number
MA37291A
Other languages
French (fr)
Other versions
MA37291A2 (en
MA37291B1 (en
Inventor
Robert Kania
John KATH
Jingrong Cui
Qinhua Huang
Michele Mctigue
Paul Richardson
Neal Sach
Benjamin Burke
Michael Collins
Judith Deal
Cynthia Palmer
Robert Hoffman
Ted Johnson
Phuong Le
Simon Bailey
Original Assignee
Pfizer Inc Etat De Delaware
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc Etat De Delaware filed Critical Pfizer Inc Etat De Delaware
Priority claimed from PCT/IB2013/051391 external-priority patent/WO2013132376A1/en
Publication of MA37291A2 publication Critical patent/MA37291A2/en
Publication of MA37291A3 publication Critical patent/MA37291A3/en
Publication of MA37291B1 publication Critical patent/MA37291B1/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des composés de formule (¦) tels que définis dans la description et des sels pharmaceutiquement acceptables de ceux-ci. Elle concerne également des compositions pharmaceutiques comprenant de tels composés et sels et les utilisations de ceux-ci. Les composés et sels de la présente invention inhibent la kinase lymphome anaplasique (alk) et/ou l'eml 4-alk et sont utiles pour traiter ou améliorer des troubles de la prolifération cellulaire anormale, tels que le cancer.The invention relates to compounds of formula (I) as defined in the description and pharmaceutically acceptable salts thereof. It also relates to pharmaceutical compositions comprising such compounds and salts and uses thereof. The compounds and salts of the present invention inhibit anaplastic lymphoma kinase (alk) and / or eml 4-alk and are useful for treating or ameliorating disorders of abnormal cell proliferation, such as cancer.

MA37291A 2012-03-06 2013-02-20 Macrocyclic derivatives for the treatment of proliferative diseases MA37291B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261607485P 2012-03-06 2012-03-06
PCT/IB2013/051391 WO2013132376A1 (en) 2012-03-06 2013-02-20 Macrocyclic derivatives for the treatment of proliferative diseases

Publications (3)

Publication Number Publication Date
MA37291A2 MA37291A2 (en) 2016-10-31
MA37291A3 true MA37291A3 (en) 2018-05-31
MA37291B1 MA37291B1 (en) 2019-01-31

Family

ID=55171500

Family Applications (1)

Application Number Title Priority Date Filing Date
MA37291A MA37291B1 (en) 2012-03-06 2013-02-20 Macrocyclic derivatives for the treatment of proliferative diseases

Country Status (2)

Country Link
MA (1) MA37291B1 (en)
UA (1) UA110293C2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112321604A (en) * 2019-08-05 2021-02-05 华东理工大学 Macrocyclic JAK2 inhibitor and application thereof

Also Published As

Publication number Publication date
UA110293C2 (en) 2015-12-10
MA37291A2 (en) 2016-10-31
MA37291B1 (en) 2019-01-31

Similar Documents

Publication Publication Date Title
MA38391A1 (en) Pyridinyl and triazolone pyridinyl derivatives of fusion
MA47079A (en) AMINO-TRIAZOLOPYIDINE COMPOUNDS AND THEIR USE TO TREAT CANCER
MA45920B1 (en) Pyridopyrimidinone cdk2 / 4/6 inhibitors
MA40111A1 (en) Derivatives of tetrahydronaphthalene inhibiting mcl-1 protein
MY169142A (en) Macrocyclic derivatives for the treatment of proliferative diseases
MA40225A (en) SUBSTITUTED DIHYDROISOQUINOLINONE COMPOUNDS
TN2014000420A1 (en) INDOLE AND INDAZOLE DERIVATIVES THAT ACTIVATE MPK
TN2014000537A1 (en) 4- (AMINO-SUBSTITUTED) - NEW 7H-PYRROLO [2,3-D] PYRIMIDINES AS INHIBITORS OF LRRK2
MA42410A (en) OXYSTEROLS AND THEIR METHODS OF USE
MA45598B1 (en) 24-hydroxy steroles substituted in position 11 for the treatment of diseases linked to the nmda receptor
MA32014B1 (en) Concentrated compounds of pyridine, pyrimidine and triazine as a cell inhibitor
MA37831B1 (en) Azaindole derivatives acting as pi3k inhibitor
AU2011297889A8 (en) Pharmaceutically active compounds as Axl inhibitors
MA37400B1 (en) Heterocyclyl compounds as mek inhibitors
MA37891A1 (en) Alcoxypyrazoles as activators of soluble guanylate cyclase
MA30952B1 (en) CYCLOPENTA [D] PYRIMIDINES USEFUL AS INHIBITORS OF PROTEIN KINASE AKT
MA29795B1 (en) INHIBITORS OF DIPEPTIDYL PEPTIDASE FOR THE TREATMENT OF DIABETES
MA29713B1 (en) DERIVATIVES OF TETRAHYDROINDOLONE AND TETRAHYDROINDAZOLONE
MA29377B1 (en) PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF HYPERPROLIFERATIVE DISORDERS
MA37742B1 (en) Derivatives of 3-substituted oestra-1,3,5 (10), 16-tetraene, processes for their preparation, pharmaceutical preparations containing them, and their use in the manufacture of medicaments
MA39165A1 (en) Benzimidazole-proline derivatives for their use in the treatment of crepuscular state syndrome
MA37291A2 (en) Macrocyclic derivatives for the treatment of proliferative diseases
MA53372B1 (en) Pyridopyrimidinenes as histamine h4 receptor inhibitors
TN2014000371A1 (en) MACROCYCLIC DERIVATIVES FOR THE TREATMENT OF PROLIFERATIVE DISEASES
MA38206B1 (en) Pyridyl hydrazones for the treatment of tuberculosis and related diseases